MBX Biosciences, Inc. (MBX)
66.30
-0.46
(-0.69%)
USD |
NASDAQ |
Aug 27, 14:42
MBX Biosciences Total Assets (Quarterly) : 435.91M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 435.91M |
| March 31, 2026 | 452.70M |
| December 31, 2025 | 385.14M |
| September 30, 2025 | 400.08M |
| June 30, 2025 | 231.52M |
| March 31, 2025 | 245.93M |
| Date | Value |
|---|---|
| December 31, 2024 | 268.54M |
| September 30, 2024 | 282.40M |
| June 30, 2024 | 62.88M |
| March 31, 2024 | 75.32M |
| December 31, 2023 | 84.18M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Amylyx Pharmaceuticals, Inc. | 264.56M |
| ANI Pharmaceuticals, Inc. | 1.494B |
| Corcept Therapeutics, Inc. | 888.70M |
| Veru, Inc. | 37.03M |
| Johnson & Johnson | 201.06B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 26.37M |
| Shareholders Equity (Quarterly) | 409.54M |
| Debt to Equity Ratio | 0.0082 |
| Current Ratio | 18.08 |
| Net Debt Paydown Yield | -0.02% |